Randomized, double‐blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3
Open Access
- 3 August 2016
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 18 (11) , 1081-1088
Abstract
Aims: To compare the efficacy and safety of basal insulin peglispro ( BIL ), which has a flat pharmacokinetic and pharmacodynamic profile and a long duration of action, with insulin glargine ( GL ) in patients with type 1 diabetes. Materials and methods: In this phase III , 52‐week, blinded study, we randomized 1114 adults with type 1 diabetes in a 3 : 2 distribution to receive either BIL (n = 664) or GL (n = 450) at bedtime, with preprandial insulin lispro, using intensive insulin management. The primary objective was to compare glycated haemoglobin ( HbA1c ) in the groups at 52 weeks, with a non‐inferiority margin of 0.4%. Results: At 52 weeks, mean (standard error) HbA1c was 7.38 (0.03)% with BIL and 7.61 (0.04)% with GL {difference −0.22% [95% confidence interval ( CI ) −0.32, −0.12]; p < 0.001}. At 52 weeks more BIL ‐treated patients reached HbA1c <7% (35% vs 26%; p < 0.001), the nocturnal hypoglycaemia rate was 47% lower (p < 0.001) and the total hypoglycaemia rate was 11% higher (p = 0.002) than in GL ‐treated patients, and there was no difference in severe hypoglycaemia rate. Patients receiving BIL lost weight, while those receiving GL gained weight [difference −1.8 kg (95% CI −2.3, −1.3); p < 0.001]. Treatment with BIL compared with GL at 52 weeks was associated with greater increases from baseline in levels of serum triglyceride [difference 0.19 mmol/l (95% CI 0.11, 0.26); p < 0.001] and alanine aminotransferase ( ALT ) levels [difference 6.5 IU /l (95% CI 4.1, 8.9), p < 0.001], and more frequent injection site reactions. Conclusions: In patients with type 1 diabetes, treatment with BIL compared with GL for 52 weeks resulted in a lower HbA1c , more patients with HbA1c levels <7%, and reduced nocturnal hypoglycaemia, but more total hypoglycaemia and injection site reactions and higher triglyceride and ALT levels.Keywords
This publication has 23 references indexed in Scilit:
- Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trialsDiabetes, Obesity and Metabolism, 2016
- Glucodynamics of long‐acting basal insulin peglispro compared with insulin glargine at steady state in patients with type 1 diabetes: substudy of a randomized crossover trialDiabetes, Obesity and Metabolism, 2016
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized TrialDiabetes Care, 2015
- Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy SubjectsDiabetes Care, 2014
- Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose MetabolismDiabetes, 2014
- Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetesDiabetes & Metabolism, 2013
- The Effect of Adjusting for Baseline Hypoglycemia when Analyzing Hypoglycemia Data: A Systematic Analysis of 15 Diabetes Clinical TrialsDiabetes Technology & Therapeutics, 2013
- General Multistage Gatekeeping ProceduresBiometrical Journal, 2008
- Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetesJournal of Diabetes and its Complications, 2007
- Defining and Reporting Hypoglycemia in DiabetesDiabetes Care, 2005